Advancing science to help protect and save lives
At Emergent BioSolutions, we develop, manufacture and deliver products that help safeguard communities, support frontline responders and empower governments to meet health challenges with confidence.
Emergent’s approach is to achieve balance in the products that we develop through a pipeline comprising innovative solutions that target diseases worldwide. We embrace the mindset that we are never done, never satisfied, never standing still when it comes to delivering quality outcomes.
Our Scientific strategy centers on:
Preparedness
Advancing medical countermeasures for biological and infectious disease threats.
Resilience
Ensuring reliable, scalable solutions across the lifecycle of product development and manufacturing.
Innovation
Collaborating with partners on emerging scientific and manufacturing technologies to accelerate time-to-impact.
Focus Areas
Our vision is to become the leader in solving health threats for communities around the world.
Our Approach
-
Our teams operate with a commitment to quality, compliance and regulatory excellence. Every R&D initiative is grounded in robust science, translational insight and cross-functional expertise.
-
We actively collaborate with U.S. and international government agencies, academic research institutions, biotechnology innovators and commercial partners to help bring critical products to the communities who need them most.
-
Quality is foundational to our R&D strategy. We prioritize investment in systems, workforce training, and process improvements that strengthen product reliability and regulatory alignment. Our science teams work hand-in-hand with quality and manufacturing organizations to ensure our innovations meet the highest standards from discovery through distribution.
Pipeline and Development Opportunities
| Product/Candidate | Disease Area | Disease Area | Stage of Development |
|---|---|---|---|
| Ebanga™ * | Zaire ebolavirus | BARDA | Approved |
| TEMBEXA® | Smallpox | BARDA | Approved |
| TEMBEXA® | Mpox | PANTHER, Africa CDC-led | Phase 2 |
| raxibacumab | Anthrax | BARDA | Approved |
| CDC Category A Agent | Undisclosed | Undisclosed partner | Preclinical |
| CDC Category B Agent | Undisclosed | Undisclosed partner | Preclinical |
| Pandemic Flu Vaccine | Flu vaccine candidate/platform to address pandemic flu | TBD candidate/partner selection | Discovery |
highlighted study
Ongoing Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
The ‘MpOx Study in Africa’ (MOSA) will evaluate the safety and efficacy of brincidofovir in treating mpox virus in a randomized double-blind placebo-controlled trial.
Partnerships
Our expertise extends beyond our own product development. We’re proud to partner with organizations around the world to deliver protective and life-saving solutions.
Partnering Areas of Interest
We partner across a range of therapeutic areas, modalities and technologies, including: